Mirabegron versus darifenacin: which is the preferred first-line treatment for overactive bladder syndrome?

Objective: Overactive bladder affects up to 32% of Latin Americans over 40.This study compares mirabegron and darifenacin in terms of safety and efficacy, as no similar studies exist in Colombia.Method: A retrospective study of 234 patients treated with mirabegron or darifenacin between January/2019 and April/2022.Data were analyzed using statistical tests, with significance set at p < 0.05.Results: Both drugs significantly reduced urination frequency, with no difference in patient-reported improvement.Women experienced more side effects, particularly with Darifenacin.Conclusions: Both treatments were effective, but Darifenacin had more side effects, leading to higher discontinuation rates for women.